21:40 , Jan 3, 2018 |  BC Innovations  |  Product R&D

Expanding small molecule horizons

With a platform boasting more than a decade of preclinical rigor and $55.3 million in series A funding, Expansion Therapeutics Inc. is the latest company to step into the RNA-binding small molecule arena. The newco...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which to...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

ISIS-DMPKRx: Phase I started

Isis began a Phase I trial of ISIS-DMPKRx. The start triggered a $14 million milestone payment to Isis from Biogen Idec Inc. (NASDAQ:BIIB, Weston, Mass.) under a June 2012 deal granting Biogen Idec an...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Biogen Idec, Isis Pharmaceuticals deal

Isis received a $10 million milestone payment from Biogen under a June 2012 deal to develop and commercialize an antisense drug candidate targeting dystrophia myotonica-protein kinase ( DMPK; DM1) to treat myotonic dystrophy type...